Cita APA (7a ed.)

A, D., JV, E., MRPT, M., HS, F., TM, Z., ML, C., & UF, M. (2020). Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Dove Medical Press.

Cita Chicago Style (17a ed.)

A, David-Silva, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Correa-Giannella ML, y Machado UF. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Dove Medical Press, 2020.

Cita MLA (8a ed.)

A, David-Silva, et al. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Dove Medical Press, 2020.